CervoMed has published two peer-reviewed papers on neflamapimod, its experimental treatment for dementia with Lewy bodies (DLB). One reports results from the placebo-controlled portion of the company’s Phase 2b RewinD-LB trial; the other describes research on the drug’s effects on inflammatory processes linked to nerve-cell damage.
The clinical findings are mixed: neflamapimod did not confirm the earlier Phase 2a result on the trial’s primary measure across the full study population. The papers also report a brain-imaging finding and a potentially more favorable result among patients with low blood levels of a marker associated with Alzheimer’s disease.
Key details
-
The Phase 2b study enrolled 159 people with DLB. Participants received neflamapimod at 40 mg three times daily or placebo. The published results are from the trial’s placebo-controlled phase.
-
The primary clinical result was not confirmed in the full study population. Neflamapimod did not confirm the Phase 2a AscenD-LB trial’s results on change in the Clinical Dementia Rating Sum of Boxes, or CDR-SB, a measure of dementia severity.
-
A subgroup without apparent Alzheimer’s disease co-pathology showed a more favorable comparison with placebo. The company identified this group using low blood levels of pTau181. The placebo-adjusted CDR-SB differences were −0.51 points for participants with pTau181 below 23 pg/mL and −0.70 points for those below 21 pg/mL. The reported confidence intervals for both estimates included zero, so the results do not establish a definitive treatment effect. The company said they were consistent with findings from its earlier Phase 2a study.
-
An MRI substudy found a difference in brain volume. Participants taking neflamapimod had a statistically significant increase in right basal forebrain volume compared with those taking placebo. The researchers described this as consistent with an effect on the underlying disease process.
-
The second paper examines inflammation-related mechanisms. Published in Cells, it reports preclinical and clinical findings that neflamapimod inhibits IL-1β signaling and affects neuroinflammatory processes implicated in cognitive decline in DLB and other neurodegenerative diseases.
-
CervoMed cited drug exposure as a factor in further development. The company said clinical, biomarker and imaging findings appeared aligned with plasma drug levels, with activity most evident at trough concentrations of about 4 ng/mL or higher.
-
The company’s proposed regimen is 100 mg twice daily using a new tablet formulation. CervoMed said it projects that this dose would bring more than 90% of participants to the target trough concentration, with more consistent exposure and without substantially increasing peak concentrations or overall exposure. This is the company’s rationale for a future regimen, not a reported result from the 40-mg three-times-daily trial.
What the findings establish
The publications add peer-reviewed detail to the evidence for neflamapimod, but the Phase 2b study did not meet the bar of confirming the earlier clinical result on its primary measure across the full population. The subgroup and imaging findings provide additional signals, while the subgroup estimates remain uncertain. The announcements concern research results and a proposed dosing approach; they do not establish that neflamapimod is an approved or proven treatment for DLB.